Volume 13, Number 6—June 2007
Research
Risk Factors for Imported Fatal Plasmodium falciparum Malaria, France, 1996–2003
Table 4
Variable | Odds ratio | 95% Confidence interval | p value |
---|---|---|---|
Age | |||
Per increase of 10 y | 1.78 | (1.56–2.02) | <0.001 |
Origin and residence | |||
African travelers | 1 | ||
African residents | 3.15 | (1.32–7.51) | |
European travelers | 6.79 | (3.49–13.2) | <0.001 |
European expatriates | 4.44 | (1.91–10.3) | |
Others | 3.02 | (1.21–7.57) | |
Region of malaria acquisition | |||
West Africa | 1 | ||
Central Africa | 0.86 | (0.52–1.41) | |
East Africa | 3.39 | (1.49–7.72) | 0.02 |
Madagascar and Comoros Islands | 0.61 | (0.24–1.53) | |
Others | 0.47 | (0.11–1.95) | |
Chemoprophylaxis | |||
Effective drugs† | 1 | ||
No chemoprophylaxis | 2.07 | (1.19–3.61) | 0.04 |
Ineffective drugs† | 1.90 | (0.91–3.95) |
*Multiple imputations were used for missing data for the variables “region of malaria acquisition” (n = 9) and “chemoprophylaxis” (n = 2,366) (see Methods).
†Effective drugs were mefloquine, atovaquone-proguanil, doxycycline, and chloroquine-proguanil; ineffective drugs were chloroquine, proguanil, pyrimethamine, and sulfadoxine-pyrimethamine.
Page created: May 31, 2011
Page updated: May 31, 2011
Page reviewed: May 31, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.